Opexa Therapeutics Company Profile (NASDAQ:OPXA)

About Opexa Therapeutics (NASDAQ:OPXA)

Opexa Therapeutics logoOpexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology. The Company's product candidates include Tcelna and OPX-212. Tcelna is an autologous T-cell immunotherapy that is being developed for the treatment of secondary progressive MS (SPMS) and is tailored to each patient's immune response profile to myelin. Tcelna is designed to reduce the number and/or functional activity of specific subsets of myelin-reactive T-cells (MRTCs) known to attack myelin. Tcelna is manufactured using its method for the production of an autologous T-cell product. In addition to the ongoing clinical development of Tcelna, the Company is developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OPXA
  • CUSIP: N/A
  • Web: www.opexatherapeutics.com
  • Market Cap: $6.82 million
  • Outstanding Shares: 7,657,000
Average Prices:
  • 50 Day Moving Avg: $0.76
  • 200 Day Moving Avg: $0.80
  • 52 Week Range: $0.50 - $4.93
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.07
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $2.18 million
  • Price / Sales: 3.09
  • Book Value: $0.29 per share
  • Price / Book: 3.03
  • EBIDTA: ($5,490,000.00)
  • Net Margins: -274.79%
  • Return on Equity: -150.46%
  • Return on Assets: -97.11%
  • Current Ratio: 3.78%
  • Quick Ratio: 3.78%
  • Average Volume: 440,781 shs.
  • Beta: 2.12
  • Short Ratio: 7.81
Frequently Asked Questions for Opexa Therapeutics (NASDAQ:OPXA)

What is Opexa Therapeutics' stock symbol?

Opexa Therapeutics trades on the NASDAQ under the ticker symbol "OPXA."

How were Opexa Therapeutics' earnings last quarter?

Opexa Therapeutics, Inc. (NASDAQ:OPXA) announced its earnings results on Friday, May, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter. Opexa Therapeutics had a negative net margin of 274.79% and a negative return on equity of 150.46%. View Opexa Therapeutics' Earnings History.

Where is Opexa Therapeutics' stock going? Where will Opexa Therapeutics' stock price be in 2017?

3 brokerages have issued 12-month price objectives for Opexa Therapeutics' stock. Their forecasts range from $6.00 to $18.00. On average, they anticipate Opexa Therapeutics' stock price to reach $11.67 in the next twelve months. View Analyst Ratings for Opexa Therapeutics.

What are analysts saying about Opexa Therapeutics stock?

Here are some recent quotes from research analysts about Opexa Therapeutics stock:

  • 1. According to Zacks Investment Research, "Opexa Therapeutics, Inc. develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for type one diabetes. " (5/24/2017)
  • 2. Maxim Group analysts commented, "Opexa reported 2Q16 with a net loss of $2.1M. The company ended the period with ~$8M in cash, sufficient runway through what we see as not just one, but two inflection points. Tcelna POC data in SPMS are expected by early 4Q, and then the decision by Merck Serono on whether to opt in and go pivotal (phase III), fund a redo" phase II study, or walk away will occur (this could take up to 60 days after data are announced)." (8/12/2016)

Who are some of Opexa Therapeutics' key competitors?

Who are Opexa Therapeutics' key executives?

Opexa Therapeutics' management team includes the folowing people:

  • Neil K. Warma, President, Chief Executive Officer, Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Director
  • Don G. Healey Ph.D.,, Chief Scientific Officer
  • Timothy C. Barabe, Independent Director
  • Hans-Peter Hartung M.D,Ph.D., Independent Director
  • Gail J. Maderis, Independent Director
  • Michael S. Richman, Independent Director

How do I buy Opexa Therapeutics stock?

Shares of Opexa Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Opexa Therapeutics' stock price today?

One share of Opexa Therapeutics stock can currently be purchased for approximately $0.88.

MarketBeat Community Rating for Opexa Therapeutics (NASDAQ OPXA)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  135
MarketBeat's community ratings are surveys of what our community members think about Opexa Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Opexa Therapeutics (NASDAQ:OPXA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $11.67 (1,225.76% upside)

Analysts' Ratings History for Opexa Therapeutics (NASDAQ:OPXA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/28/2016Maxim GroupDowngradeBuy -> HoldN/AView Rating Details
10/28/2016Chardan CapitalDowngradeBuy -> NeutralN/AView Rating Details
10/28/2016AegisDowngradeBuy -> HoldN/AView Rating Details
(Data available from 7/28/2015 forward)


Earnings History for Opexa Therapeutics (NASDAQ:OPXA)
Earnings by Quarter for Opexa Therapeutics (NASDAQ:OPXA)
Earnings History by Quarter for Opexa Therapeutics (NASDAQ OPXA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/12/2017Q1 2017($0.12)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.25)($0.28)$0.73 millionViewN/AView Earnings Details
8/11/2016Q216($0.23)($0.30)$0.73 million$0.73 millionViewListenView Earnings Details
5/12/2016Q116($0.35)($0.31)$0.73 million$0.73 millionViewListenView Earnings Details
3/15/2016Q415($0.50)($2.05)$0.73 million$0.73 millionViewListenView Earnings Details
11/10/2015Q315($2.48)($0.42)$0.73 million$0.73 millionViewN/AView Earnings Details
8/12/2015Q215($0.08)($0.07)$0.73 millionViewListenView Earnings Details
5/12/2015Q1($0.15)($0.12)$0.38 millionViewListenView Earnings Details
11/6/2014($0.14)($0.12)$0.30 million$0.31 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.15)$0.30 million$0.31 millionViewN/AView Earnings Details
5/14/2014Q114($0.13)($0.13)$0.22 million$0.35 millionViewN/AView Earnings Details
8/14/2013Q213($0.37)$0.35 millionViewN/AView Earnings Details
11/14/2012Q312($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Opexa Therapeutics (NASDAQ:OPXA)
Current Year EPS Consensus Estimate: $-1.13 EPS
Next Year EPS Consensus Estimate: $-0.82 EPS


Dividend History for Opexa Therapeutics (NASDAQ:OPXA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Opexa Therapeutics (NASDAQ:OPXA)
Insider Ownership Percentage: 6.88%
Institutional Ownership Percentage: 4.09%
Insider Trades by Quarter for Opexa Therapeutics (NASDAQ:OPXA)
Insider Trades by Quarter for Opexa Therapeutics (NASDAQ:OPXA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/18/2016Timothy C BarabeDirectorSell14,914$0.55$8,202.70View SEC Filing  
9/17/2014Timothy C BarabeDirectorBuy10,000$1.15$11,500.00View SEC Filing  
9/16/2014Neil K WarmaCEOBuy10,000$1.11$11,100.00View SEC Filing  
12/18/2013Karthik RadhakrishnanCFOBuy8,000$1.70$13,600.00View SEC Filing  
12/18/2013Scott B SeamanDirectorBuy30,000$1.70$51,000.00View SEC Filing  
8/8/2013Karthik RadhakrishnanCFOBuy50,000$1.50$75,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Opexa Therapeutics (NASDAQ:OPXA)
Latest Headlines for Opexa Therapeutics (NASDAQ:OPXA)
streetinsider.com logoOpexa Therapeutics (OPXA) Enters Merger Deal with Acer ... - StreetInsider.com
www.streetinsider.com - July 5 at 9:18 AM
streetinsider.com logoOpexa Therapeutics (OPXA) Enters Merger Deal with Acer Therapeutics
www.streetinsider.com - July 4 at 3:02 AM
rttnews.com logoOpexa Therapeutics Inc. (OPXA) Is Surging After Merger Agreement
www.rttnews.com - July 4 at 3:02 AM
finance.yahoo.com logoAcer Therapeutics and Opexa Therapeutics Sign Merger Agreement
finance.yahoo.com - July 4 at 3:02 AM
finance.yahoo.com logo​Cambridge rare disease startup Acer to go public through merger
finance.yahoo.com - July 4 at 3:02 AM
americanbankingnews.com logoOpexa Therapeutics Inc (OPXA) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - May 27 at 9:28 PM
americanbankingnews.com logoOpexa Therapeutics Inc (OPXA) Posts Quarterly Earnings Results
www.americanbankingnews.com - May 15 at 11:18 AM
reuters.com logoBRIEF-Opexa Therapeutics quarterly loss per share $0.12
www.reuters.com - May 13 at 12:51 AM
finance.yahoo.com logoOpexa Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 12 at 7:47 PM
americanbankingnews.com logoOpexa Therapeutics (OPXA) Receives Daily News Sentiment Score of -0.02
www.americanbankingnews.com - May 1 at 3:28 PM
americanbankingnews.com logoOpexa Therapeutics (OPXA) Getting Positive News Coverage, Study Shows
www.americanbankingnews.com - April 29 at 1:19 AM
americanbankingnews.com logoOpexa Therapeutics (OPXA) Earns News Sentiment Rating of 0.44
www.americanbankingnews.com - April 21 at 7:14 PM
americanbankingnews.com logoFavorable Media Coverage Somewhat Likely to Impact Opexa Therapeutics (OPXA) Share Price
www.americanbankingnews.com - April 15 at 10:07 AM
americanbankingnews.com logoOpexa Therapeutics Inc (OPXA) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 14 at 10:06 AM
americanbankingnews.com logoOpexa Therapeutics Inc (OPXA) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 5 at 12:13 PM
americanbankingnews.com logoOpexa Therapeutics Inc (OPXA) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 3 at 9:23 AM
finance.yahoo.com logoOPEXA THERAPEUTICS, INC. Financials
finance.yahoo.com - April 2 at 10:53 AM
finance.yahoo.com logoOpexa Therapeutics Reports 2016 Year End Financial Results and Provides Corporate Update
finance.yahoo.com - March 28 at 6:50 PM
biz.yahoo.com logoOPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
biz.yahoo.com - March 28 at 6:50 PM
biz.yahoo.com logoOPEXA THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisitio
biz.yahoo.com - February 8 at 7:58 PM
finance.yahoo.com logoOpexa Facility Becomes Foundation for Contract Manufacturing and Development Organization for Cellular Therapies
finance.yahoo.com - February 1 at 8:13 PM



Opexa Therapeutics (OPXA) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff